Drug Trial Radar · NCT03168438
Letetresgene Autoleucel Engineered T Cells Alone and in Combination With Pembrolizumab in NY-ESO-1 Positive Multiple Myeloma
Last checked: Nov 20, 2026Latest source record: Jan 11, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
6
Actual
Start
Aug 18, 2017
Primary completion
Jul 13, 2020
Study completion Nov 5, 2020
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- Collaborators
- Merck Sharp & Dohme LLC
- First posted
- May 30, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This trial will evaluate safety, tolerability, and efficacy of letetresgene autoleucel (GSK3377794) with or without pembrolizumab in participants with relapsed and refractory multiple myeloma.
Conditions
- Neoplasms
Interventions
Letetresgene autoleucelDrug
Letetresgene autoleucel (GSK3377794) as an IV infusion
Letetresgene autoleucel with pembrolizumabDrug
Letetresgene autoleucel (GSK3377794) as an IV infusion, followed by pembrolizumab every 3 weeks
FludarabineDrug
Fludarabine will be used as lymphodepleting chemotherapy and will be administered via IV route.
CyclophosphamideDrug
Cyclophosphamide will be used as lymphodepleting chemotherapy and will be administered via IV route.
PembrolizumabDrug
Pembrolizumab is available as an IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)Time frame: Up to 108 weeks
- Number of Participants With Treatment Limiting Toxicities-GSK3377794+Pembrolizumab Arm OnlyTime frame: Up to 3 weeks
- Number of Participants With Worst-case Chemistry Results by Any Grade Increase Post-Baseline Relative to BaselineTime frame: Up to 108 weeks
- Number of Participants With Worst-case Hematology Results by Any Grade Increase Post-Baseline Relative to BaselineTime frame: Up to 108 weeks
- Number of Participants With Worst-case Results for Coagulation Parameters Relative to Normal Range Post-Baseline Relative to BaselineTime frame: Up to 108 weeks
- Number of Participants With Worst-case Post Baseline Abnormal Electrocardiogram (ECG) FindingsTime frame: Up to 108 weeks
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
GSK Investigational Site
Duarte, California
GSK Investigational Site
Miami, Florida
GSK Investigational Site
Tampa, Florida
GSK Investigational Site
Atlanta, Georgia
GSK Investigational Site
Baltimore, Maryland
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.